

TABLES

I.1 Clinical Areas in QA Tools System By Covered Population Group.....4
I.2 Dates Expert Panels Convened.....10
I.3 Distribution of Indicators (%) by Level of Evidence.....11
I.4 Distribution of Indicators (%) by Type of Care.....12
I.5 Distribution of Indicators (%) by Function of Medicine.....12
I.6 Distribution of Indicators (%) by Modality.....13
I.7 Clinical Areas Covered by Each Expert Panel.....14
I.8 Clinical Guidelines versus Quality Indicators.....16
I.9 Disposition of Proposed Oncology and HIV Quality Indicators by
Strength of Evidence.....19
I.10 Distribution of Final Oncology and HIV Quality Indicators by Type
of Care, Function, and Modality.....23
2.1 Definitions for Breast Cancer Staging.....36
2.2 Classification of Breast Cancer Stages.....36
3.1 Cytopathology Reporting Systems for Pap Smears.....50
4.1 Clinical Trials of Fecal Occult Blood Tests.....67
4.2 Computer model of clinical consequences of 100,000 people entering
a program of screening for CRC at age 50 years and remaining in it
until age 85 or death.....69
5.1 Definition of Stages of Colorectal Cancer.....79
7.1 Histologic Types Of Lung Cancer.....136
7.2 Definition Of Stages Of Non-Small Cell Lung Cancer.....149
7.3 Definition of Stages of Small Cell Lung Cancer.....151
8.1 Organizational Recommendations Regarding Prostate Cancer Screening...181
9.1 Definition of Stages of Prostate Cancer.....204
11.1 Severely and Highly Emetogenic Chemotherapy Agents.....231

FIGURES

Figure I.1 - Sample Panelist Summary Rating Sheet.....9
Figure I.2 - Sample Rating Results Sheet.....21